Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

2.

Insufficient uptake of systematic search methods in oncological clinical practice guideline: a systematic review.

Trevisiol C, Cinquini M, Fabricio ASC, Gion M, Rutjes AWS.

BMC Med Res Methodol. 2019 Aug 20;19(1):180. doi: 10.1186/s12874-019-0818-5.

3.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

4.

Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels.

Fabricio ASC, Michilin S, Zancan M, Agnolon V, Peloso L, Dittadi R, Scapinello A, Ceccarelli C, Gion M.

Scand J Clin Lab Invest. 2019 Jul;79(4):260-267. doi: 10.1080/00365513.2019.1600200. Epub 2019 Apr 15.

PMID:
30982358
5.

Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination.

Dittadi R, Fabricio ASC, Rainato G, Peroni E, Di Tonno F, Vezzù B, Mazzariol C, Squarcina E, Tammone L, Gion M.

Clin Chem Lab Med. 2019 Mar 26;57(4):521-531. doi: 10.1515/cclm-2018-0596.

PMID:
30218601
6.

Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E.

BMC Cancer. 2018 Sep 10;18(1):876. doi: 10.1186/s12885-018-4799-2.

7.

Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E.

BMC Cancer. 2018 Jun 13;18(1):651. doi: 10.1186/s12885-018-4558-4. Erratum in: BMC Cancer. 2018 Sep 10;18(1):876.

8.

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.

Pastorelli D, Fabricio ASC, Giovanis P, D'Ippolito S, Fiduccia P, Soldà C, Buda A, Sperti C, Bardini R, Da Dalt G, Rainato G, Gion M, Ursini F.

Pharmacol Res. 2018 Jun;132:72-79. doi: 10.1016/j.phrs.2018.03.013. Epub 2018 Mar 31.

PMID:
29614381
9.

Clinical evaluation of the iXip index to reduce prostate re-biopsies.

Galosi AB, Dell'Atti L, Bertaccini A, Gion M, Francavilla S, Ferretti S, Maestroni U, Gallotta A, Parrozzani C, Paneghetti L, Fassina G.

Cancer Treat Res Commun. 2018;16:59-63. doi: 10.1016/j.ctarc.2018.07.001. Epub 2018 Jul 19.

PMID:
31299004
10.

Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice.

Ferraro S, Trevisiol C, Gion M, Panteghini M.

Clin Chem. 2018 Feb;64(2):270-278. doi: 10.1373/clinchem.2017.275263. Epub 2017 Oct 11. Review.

11.

Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making.

Mustafa RA, Wiercioch W, Ventresca M, Brozek J, Schünemann HJ; DU-Diagnosis expert group.

J Clin Epidemiol. 2017 Dec;92:47-57. doi: 10.1016/j.jclinepi.2017.09.005. Epub 2017 Sep 14. Review.

PMID:
28917629
12.

Appropriateness of tumor marker request: a case of study.

Gion M, Trevisiol C, Fabricio ASC.

Ann Transl Med. 2017 Jul;5(13):274. doi: 10.21037/atm.2017.06.19.

13.

Epidemiology-based assessment of tumor marker overordering in breast cancer: an algorithm to examine different disease conditions.

Trevisiol C, Gion M, Dittadi R, Zappa M, Fabricio ASC.

Int J Biol Markers. 2017 Oct 31;32(4):e471-e473. doi: 10.5301/ijbm.5000274.

PMID:
28561878
14.

Indicators of inappropriate tumour marker use through the mining of electronic health records.

Gion M, Cardinali G, Trevisiol C, Zappa M, Rainato G, Fabricio ASC.

J Eval Clin Pract. 2017 Aug;23(4):895-902. doi: 10.1111/jep.12754. Epub 2017 May 15.

PMID:
28503788
15.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 3).

Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC.

Int J Biol Markers. 2017 May 4;32(2):e147-e181. doi: 10.5301/ijbm.5000272. No abstract available.

PMID:
28475208
16.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 2).

Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC.

Int J Biol Markers. 2017 Mar 2;32(1):e1-e52. doi: 10.5301/ijbm.5000259. No abstract available.

PMID:
28255982
17.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 1)

Gion M, Trevisiol C, Rutjes AW, Rainato G, Fabricio AS.

Int J Biol Markers. 2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251. No abstract available. Erratum in: Int J Biol Markers. 2017 Oct 31;32(4):e478.

PMID:
28025819
18.

Need for knowledge translation to improve tumor marker application.

Gion M.

Int J Biol Markers. 2016 Dec 23;31(4):e331. doi: 10.5301/jbm.5000250. No abstract available.

PMID:
28025818
19.

Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis.

Rainato G, Fabricio AS, Zancan M, Peloso L, Dittadi R, Barichello M, Fandella A, Scattoni V, Gion M.

Int J Biol Markers. 2016 Jul 30;31(3):e317-23. doi: 10.5301/jbm.5000200.

PMID:
26954072
20.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.

Gynecol Oncol. 2016 May;141(2):303-311. doi: 10.1016/j.ygyno.2016.01.016. Epub 2016 Jan 19.

PMID:
26801941

Supplemental Content

Loading ...
Support Center